CytoMed Therapeutics Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
42
- Stock Symbol
-
GDTC
- Investments
-
1
- Share Price
-
$0.77
- (As of Monday Closing)
CytoMed Therapeutics General Information
Description
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Contact Information
Website
www.w2.cytomed.sgCorporate Office
- 1 Commonwealth Lane
- No. 08-22 One Commonwealth
- Singapore, 149544
- Singapore
Corporate Office
- 1 Commonwealth Lane
- No. 08-22 One Commonwealth
- Singapore, 149544
- Singapore
CytoMed Therapeutics Stock Performance
As of 16-Nov-2026, CytoMed Therapeutics’s stock price is $0.77. Its current market cap is $9.2M with 11.9M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.77 | $0.83 | $0.68 - $2.29 | $9.2M | 11.9M | 17.1K | -$0.23 |
CytoMed Therapeutics Financials Summary
As of 30-Jun-2026, CytoMed Therapeutics has a trailing 12-month revenue of $254K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 11,173 | 13,870 | 34,782 | 49,145 |
| Revenue | 254 | 248 | 52 | 0 |
| EBITDA | (2,424) | (2,829) | (1,859) | (2,967) |
| Net Income | (2,731) | (3,045) | (1,883) | (3,077) |
| Total Assets | 5,425 | 6,214 | 7,405 | 9,365 |
| Total Debt | 892 | 376 | 341 | 339 |
CytoMed Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CytoMed Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
CytoMed Therapeutics Comparisons
Industry
Financing
Details
CytoMed Therapeutics Competitors (6)
One of CytoMed Therapeutics’s 6 competitors is Fate Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Fate Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Century Therapeutics | Formerly VC-backed | Philadelphia, PA | ||||
| Autolus | Formerly VC-backed | London, United Kingdom | ||||
| Bristol-Myers Squibb | Corporation | Princeton, NJ | ||||
| Gilead | Formerly VC-backed | Foster City, CA |
CytoMed Therapeutics Signals
CytoMed Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
CytoMed Therapeutics Investments (1)
CytoMed Therapeutics’s most recent deal was a Corporate Asset Purchase with TC BioPharm (Portfolio of Synergistic Assets). The deal was made on 18-Nov-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| TC BioPharm (Portfolio of Synergistic Assets) | 18-Nov-2025 | Corporate Asset Purchase | Buildings and Property |
CytoMed Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
CytoMed Therapeutics FAQs
-
When was CytoMed Therapeutics founded?
CytoMed Therapeutics was founded in 2018.
-
Where is CytoMed Therapeutics headquartered?
CytoMed Therapeutics is headquartered in Singapore, Singapore.
-
What is the size of CytoMed Therapeutics?
CytoMed Therapeutics has 42 total employees.
-
What industry is CytoMed Therapeutics in?
CytoMed Therapeutics’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is CytoMed Therapeutics a private or public company?
CytoMed Therapeutics is a Public company.
-
What is CytoMed Therapeutics’s stock symbol?
The ticker symbol for CytoMed Therapeutics is GDTC.
-
What is the current stock price of CytoMed Therapeutics?
As of 16-Nov-2026 the stock price of CytoMed Therapeutics is $0.77.
-
What is the current market cap of CytoMed Therapeutics?
The current market capitalization of CytoMed Therapeutics is $9.2M.
-
What is CytoMed Therapeutics’s current revenue?
The trailing twelve month revenue for CytoMed Therapeutics is $254K.
-
Who are CytoMed Therapeutics’s competitors?
Fate Therapeutics, Century Therapeutics, Autolus, Bristol-Myers Squibb, and Gilead are some of the 6 competitors of CytoMed Therapeutics.
-
What is CytoMed Therapeutics’s annual earnings per share (EPS)?
CytoMed Therapeutics’s EPS for 12 months was -$0.23.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process